Author name: Claritas Rx

pfizer glp-1 drug developmemt

Pfizer’s Bold Move in the Obesity Drug Market

Within a sector populated by many market pioneers promoting injectable solutions, Pfizer is redefining the landscape with an oral medication for obesity. This article explores Pfizer‘s strategic moves towards securing a prominent position in the obesity treatment market, focusing especially on their groundbreaking work on a GLP-1 drug. Introduction Pfizer, a titan in the pharmaceutical […]

Pfizer’s Bold Move in the Obesity Drug Market Read More »

competitive insights

Unlocking Competitive Data Insights in Therapy Basket Fill Rates

In the biopharma industry, understanding how your therapy basket’s fill rate stacks up against competitors can be a game-changer. This blog post dives deep into the significance of therapy basket fill rates, providing exclusive data insights and practical tips to help biopharma executives stay ahead in the competitive landscape. The Importance of Therapy Basket Fill

Unlocking Competitive Data Insights in Therapy Basket Fill Rates Read More »

calquence mcl

AstraZeneca’s Calquence Sets New Standard for Lymphoma

Mantle cell lymphoma (MCL) is a rare yet aggressive form of non-Hodgkin lymphoma, and treatment options have been limited for far too long. For pharmaceutical professionals and biopharma executives, staying at the forefront of treatment innovations is crucial. Recently, AstraZeneca has made significant strides with its BTK inhibitor, Calquence, challenging the current standard of care

AstraZeneca’s Calquence Sets New Standard for Lymphoma Read More »

fda guide

FDA Draft Guidance: Fast-Track Cell and Gene Therapies

The FDA unveiled a much-anticipated draft guide, outlining how businesses can secure approvals for platform technologies. This regulatory advance has the potential to fast-track the FDA’s ‘platform technology’ procedure, potentially accelerating the endorsement of cell and gene therapies. Keen to find out more? This comprehensive 15-page draft guide provides a wealth of knowledge for biopharma

FDA Draft Guidance: Fast-Track Cell and Gene Therapies Read More »

FDA Approves Amgen’s Bkemv

FDA Approves Amgen’s First Interchangeable Biosimilar

The U.S. Food and Drug Administration (FDA) has given the green light to Amgen’s monoclonal antibody Bkemv, the first interchangeable biosimilar for Alexion’s top-selling drug Soliris. This provides a pathway for more affordable treatments for rare blood diseases. Let’s take a closer look at what this means for the industry, medical practitioners, and patients. Deciphering

FDA Approves Amgen’s First Interchangeable Biosimilar Read More »

Depemokimab

GSK’s New Asthma Drug Clears Two Phase 3 Trials

Tuesday brought good news for asthma sufferers and the healthcare community alike, courtesy of GSK. The pharmaceutical firm announced the successful reduction of annual asthma attacks in two pivotal clinical trials of its experimental antibody treatment named Depemokimab. The trials involved adults and adolescents afflicted with a form of severe asthma. GSK’s newly developed long-lasting

GSK’s New Asthma Drug Clears Two Phase 3 Trials Read More »

AI-powered drug R&D software

Big Pharma and Tech: Unlocking AI for Drug Development

In an exciting development for the biopharma industry, Sanofi, OpenAI, and Formation Bio have announced a unique partnership aiming to develop AI-powered drug R&D software. This strategic alliance is a testament to the increasingly intertwined future of the technology and pharmaceutical sectors. This announcement follows closely on the heels of OpenAI’s other significant alliance with

Big Pharma and Tech: Unlocking AI for Drug Development Read More »

gene and cell therapy

Walgreens Diversifies into Gene and Cell Therapies

Walgreens, a powerhouse in the retail and wholesale pharmaceutical sector, embarked on an unprecedented path with an impressive service upgrade – the incorporation of gene and cell therapies. This strategy extends Walgreens’ existing service portfolio and significantly advances healthcare. Let’s explore this groundbreaking endeavor and what it means for customers. Walgreens is expanding its specialty

Walgreens Diversifies into Gene and Cell Therapies Read More »